About us

Founded in 2021 and led by a team of veteran biotherapeutics developers and protein engineers, Engimmune couples AI-guided innovation and laboratory insights to unlock the therapeutic potential of soluble TCR engagers. The company’s foundational technology is based on inventions by Dr. Rodrigo Vazquez-Lombardi and Prof. Sai Reddy. Engimmune closed its seed financing round in May 2022, which was co-led by Pureos Bioventures and Novo Holdings, and has since established a robust and differentiated pipeline of soluble TCR therapeutics.